• In comparison to the last quarter, the average HbA1c(glycosylated hemoglobin) level decreased from 8.49%to 8.28% in April to June period
12th October 2020, Hyderabad: The latest findings of the India Diabetes Care Index (IDCI®) suggest that glycosylated hemoglobin or HbA1c level decreased from 8.49% to 8.28% in April to June 2020 in Hyderabad than the previous quarter.IDCI® is a part of the ‘Impact India: 1000-Day Challenge’ programme by Novo Nordisk India and serves as a guiding tool for the status of diabetes care across multiple cities, states, and the country as a whole.
The HbA1c value gives an idea about the average blood glucose level over three months in an individual and is one of the best–recommended indicators of long-term blood glucose control. Approximately 300 people with an average age of 51years were part of the assessment in Hyderabad, out of which 71% were male, and 29% were female. Furthermore, the average postprandial glucose level in the quarter was 253mg/dl, and the average fasting glucose level was 170 mg/dl.
Speaking about the decreased HbA1c level in Hyderabad, Dr. D. Vijay Sheker Reddy, Professor & Head, Department of Endocrinology, Gandhi Medical College & Hospital, KNR University of Health Sciences and Consultant Endocrinologist, said, “The finding of the IDCI® data is very positive and it clearly shows that with some extra efforts, diabetes can be managed even during these unprecedented times within the confines of one’s home. I hope that this trend of decrease in average HbA1c level continues.”
The improving trend in HbA1c level is a sign of relief as people with diabetes have a higher risk of developing severe complications from COVID-19. It has been shown that older adults and people with pre-existing medical conditions like hypertension, heart disease and pulmonary disorders and obesity–related conditions are also at a higher risk of experiencing severe complications due to COVID-19.
People with diabetes should maintain an adequate stock of medications and supplies for monitoring blood glucose at home. Any warning signs like difficulty in breathing or shortness of breath, fever, dry cough, tiredness, aches and pains, sore throat, headache, loss of taste or smell etc. should not be ignored and medical attention should be sought immediately.
At present, more than 77 million people are living with diabetes in India. The Government of India has made provisions for all known/ diagnosed people with diabetes to receive a regular supply of medicines for up to three months through ASHAs or SHCs on prescription. Talking about the IDCI programme, Dr Anil Shinde, Trustee, Novo Nordisk Education Foundation said, “The quarterly data generated through IDCI®, as a part of theIMPACT India programme has helped us identify the trend in HbA1c level across major cities in the country. We have also observed that people with diabetes in cities like Jaipur, Chandigarh, Goa, Kolkata and Guwahati have been able to maintain low HbA1c level in the current scenario by following a strict regimen involving a healthy diet and regular exercising. An optimum practice of diabetes management at home is recommended right now as our medical systems are inundated with tackling the COVID-19 pandemic.”
The ‘Impact India: 1000-Day Challenge’ programme was launched in November 2018 to address the issue of sub-optimally controlled diabetes in India. The programme aims to reduce the national average of HbA1c by 1%, which can help decrease the risk of diabetes-related complications. Based on big data analytics, iDCI® has been providing a real-time view of the average HbA1c in India across select cities. Under the Impact India programme, digital platforms are being leveraged to partner with healthcare practitioners (doctors and paramedics) to evolve and implement an approach to diabetes care appropriate for India. iDCI® is a dynamic tool that not only tracks the status of diabetes care but
also helps to increase awareness, motivate and sensitize the healthcare professionals (HCPs) and society. The IMPACT India programme will continue its three-pronged approach over the next one year through interactions with healthcare practitioners (HCPs), societal/patient engagement and monitoring.
About Novo Nordisk Education Foundation
The Novo Nordisk Education Foundation (NNEF) was founded in 1997 with a mission to “enhance healthcare through awareness and education”. NNEF drives several projects including the Changing Diabetes® Barometer, Changing Diabetes® in Children programmes and World Diabetes Day awareness activities in partnership with state governments and other key stakeholders. As a result of these efforts, more than 750,000 people have been reached; nearly 4000 doctors and paramedics have been trained and over 100 community diabetes centres have been established. Under the Changing Diabetes® in Children programme, more than 4000 children have been receiving free treatment and care since 2011. Taking the commitment to care further, NNEF launched “IMPACT India”, a solution-oriented programme on the eve of World Diabetes Day in 2018 with an ambition to reduce the average HbA1c of the country by 1% over a three-year period.
For more information visit: nnef.in
For more information about Novo Nordisk contact:
Akriti Agrawal, Associate Manager – Corporate Communications, firstname.lastname@example.org